Literature DB >> 25263523

Integrin αvβ3 mediates the synergetic regulation of core-binding factor α1 transcriptional activity by gravity and insulin-like growth factor-1 through phosphoinositide 3-kinase signaling.

Zhongquan Dai1, Feima Guo2, Feng Wu3, Hongjie Xu4, Chao Yang5, Jinqiao Li6, Peilong Liang7, Hongyu Zhang8, Lina Qu9, Yingjun Tan10, Yumin Wan11, Yinghui Li12.   

Abstract

Mechanical stimulation and biological factors coordinately regulate bone development and regeneration; however, the underlying mechanisms are poorly understood. Microgravity induces bone loss, which may be partly related to the development of resistance to local cytokines, including insulin-like growth factor 1 (IGF-1). Here, we report the involvement of integrin αvβ3 in microgravity-associated bone loss. An established OSE-3T3 cell model was stably transfected with a 6OSE2 (Osteoblast-Specific Element 2)-luciferase reporter and cultured under simulated microgravity (SMG) and hypergravity (HG) conditions in the presence or absence of IGF-1, the disintegrin echistatin, the phosphoinositide 3-kinase (PI3K) inhibitor LY294002, or combinations of these agents. Activity of core-binding factor α1 (Cbfa1), an essential transcription factor for osteoblastic differentiation and osteogenesis, was reflected by luciferase activity. Different gravity conditions affected the induction of IGF-1 and subsequent effects on Cbfa1 transcription activity. SMG and HG influenced the expression and activity of integrin αvβ3 and phosphorylation level of p85. LY294002 inhibited the effects of HG or IGF-1 on Cbfa1 activity, indicating that HG and IGF-1 could increase Cbfa1 activity via PI3K signaling. Inhibition of integrin αvβ3 by echistatin attenuated the induction of IGF-1 and thus its effect on Cbfa1 activity under normal and HG conditions. Co-immunoprecipitation demonstrated that integrin β3 interacted with insulin receptor substrate 1, and that this interaction was decreased under SMG and increased under HG conditions. These results suggest that integrin αvβ3 mediates the synergetic regulation of Cbfa1 transcription activity by gravity and IGF-1 via PI3K signaling.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone loss; Cbfa1; Gravity; IGF-1; Integrin αvβ3; Synergetic regulation

Mesh:

Substances:

Year:  2014        PMID: 25263523     DOI: 10.1016/j.bone.2014.09.018

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  4 in total

Review 1.  Extraterrestrial Gynecology: Could Spaceflight Increase the Risk of Developing Cancer in Female Astronauts? An Updated Review.

Authors:  Rosa Drago-Ferrante; Riccardo Di Fiore; Fathi Karouia; Yashwanth Subbannayya; Saswati Das; Begum Aydogan Mathyk; Shehbeel Arif; Ana Paula Guevara-Cerdán; Allen Seylani; Aman Singh Galsinh; Weronika Kukulska; Joseph Borg; Sherif Suleiman; David Marshall Porterfield; Andrea Camera; Lane K Christenson; April Elizabeth Ronca; Jonathan G Steller; Afshin Beheshti; Jean Calleja-Agius
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

2.  The Thyroid Hormone Receptor-RUNX2 Axis: A Novel Tumor Suppressive Pathway in Breast Cancer.

Authors:  Eric L Bolf; Noelle E Gillis; Michael S Barnum; Caitlin M Beaudet; Grace Y Yu; Jennifer A Tomczak; Janet L Stein; Jane B Lian; Gary S Stein; Frances E Carr
Journal:  Horm Cancer       Date:  2019-12-21       Impact factor: 3.869

3.  Echistatin prevents posterior capsule opacification in diabetic rabbit model via integrin linked kinase signaling pathway.

Authors:  Fengbin Lin; Yingying Chen; Hao Liang; Shaojian Tan
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

4.  Hypergravity and microgravity exhibited reversal effects on the bone and muscle mass in mice.

Authors:  Tsukasa Tominari; Ryota Ichimaru; Keita Taniguchi; Akane Yumoto; Masaki Shirakawa; Chiho Matsumoto; Kenta Watanabe; Michiko Hirata; Yoshifumi Itoh; Dai Shiba; Chisato Miyaura; Masaki Inada
Journal:  Sci Rep       Date:  2019-04-29       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.